We advised the underwriters on the investment-grade debt offering

Davis Polk advised representatives of the several underwriters in connection with an SEC-registered offering by PerkinElmer of $500 million of 0.550% senior notes due 2023, $800 million of 0.850% senior notes due 2024, $500 million of 1.900% senior notes due 2028 and $500 million of 2.250% senior notes due 2031. The net proceeds from the offering were approximately $2.28 billion, which PerkinElmer intends to use to pay a portion of the cash consideration payable for its acquisition of BioLegend, Inc. a global developer and manufacturer of antibodies and reagents used in biomedical research.

PerkinElmer, headquartered in Waltham, Massachusetts, is a global corporation focused on diagnostics, life science research, food and environmental and industrial testing. PerkinElmer produces analytical instruments, genetic testing and diagnostic tools, medical imaging components, software and consumables for multiple end markets.

The Davis Polk corporate team included partner John G. Crowley and associates Rahul K. Patel and Shua Mermelstein. Partner Po Sit provided tax advice. Partner Pritesh P. Shah and associates Yana Kipnis and Marisa Elena Bannon provided intellectual property advice. Counsel David A. Zilberberg provided environmental advice. All members of the Davis Polk team are based in the New York office.